Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position (Form 8-K)

Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position

NEW HAVEN, CT, Globenewswire - (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026.

Below are some of the key financial performance metrics for the Company. For additional results please see the Company's Form 10-Q which was filed today.

"As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history. Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M." said Ilan Danieli, CEO of Precipio. "We've achieved this level of cash without a financing event, demonstrating the strength of our operations. We're encouraged by the progress we've made and believe we are well positioned to continue building on this momentum."

Additional information and a more in-depth discussion on the Company's Q2-2026 performance will be provided in the shareholder call on August 17th, 2026, at 5 PM ET. The call will include remarks by management on the Company's core business, followed by a moderated Q&A session.

EBITDA and Adjusted EBITDA Reconciliation and Explanation

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company's financial health, particularly where non-cash amortization has an important impact on profitability.

Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the second quarter of 2026 and 2025:

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.